538 related articles for article (PubMed ID: 27478924)
1. Serious adverse events reported for antiobesity medicines: postmarketing experiences from the EU adverse event reporting system EudraVigilance.
Aagaard L; Hallgreen CE; Hansen EH
Int J Obes (Lond); 2016 Nov; 40(11):1742-1747. PubMed ID: 27478924
[TBL] [Abstract][Full Text] [Related]
2. Consumer reporting of adverse drug reactions: a retrospective analysis of the Danish adverse drug reaction database from 2004 to 2006.
Aagaard L; Nielsen LH; Hansen EH
Drug Saf; 2009; 32(11):1067-74. PubMed ID: 19810778
[TBL] [Abstract][Full Text] [Related]
3. Adverse drug reactions in the paediatric population in Denmark: a retrospective analysis of reports made to the Danish Medicines Agency from 1998 to 2007.
Aagaard L; Weber CB; Hansen EH
Drug Saf; 2010 Apr; 33(4):327-39. PubMed ID: 20297864
[TBL] [Abstract][Full Text] [Related]
4. The cardiovascular safety of antiobesity drugs-analysis of signals in the FDA Adverse Event Report System Database.
Gorelik E; Gorelik B; Masarwa R; Perlman A; Hirsh-Raccah B; Matok I
Int J Obes (Lond); 2020 May; 44(5):1021-1027. PubMed ID: 32152496
[TBL] [Abstract][Full Text] [Related]
5. Adverse drug reactions reported by consumers for nervous system medications in Europe 2007 to 2011.
Aagaard L; Hansen EH
BMC Pharmacol Toxicol; 2013 Jun; 14():30. PubMed ID: 23763896
[TBL] [Abstract][Full Text] [Related]
6. Spontaneous reports of vaccination errors in the European regulatory database EudraVigilance: A descriptive study.
Hoeve CE; van Haren A; Sturkenboom MCJM; Straus SMJM
Vaccine; 2018 Dec; 36(52):7956-7964. PubMed ID: 30416019
[TBL] [Abstract][Full Text] [Related]
7. Evaluation of patient reporting of adverse drug reactions to the UK 'Yellow Card Scheme': literature review, descriptive and qualitative analyses, and questionnaire surveys.
Avery AJ; Anderson C; Bond CM; Fortnum H; Gifford A; Hannaford PC; Hazell L; Krska J; Lee AJ; McLernon DJ; Murphy E; Shakir S; Watson MC
Health Technol Assess; 2011 May; 15(20):1-234, iii-iv. PubMed ID: 21545758
[TBL] [Abstract][Full Text] [Related]
8. Descriptive analysis of reported adverse events associated with anti-obesity medications using FDA Adverse Event Reporting System (FAERS) databases 2013-2020.
Alsuhibani A; Alrasheed M; Gari M; Hincapie AL; Guo JJ
Int J Clin Pharm; 2022 Feb; 44(1):172-179. PubMed ID: 34564826
[TBL] [Abstract][Full Text] [Related]
9. Adverse events with sodium-glucose co-transporter-2 inhibitors: A global analysis of international spontaneous reporting systems.
Raschi E; Parisotto M; Forcesi E; La Placa M; Marchesini G; De Ponti F; Poluzzi E
Nutr Metab Cardiovasc Dis; 2017 Dec; 27(12):1098-1107. PubMed ID: 29174026
[TBL] [Abstract][Full Text] [Related]
10. Patient Reporting in the EU: Analysis of EudraVigilance Data.
Banovac M; Candore G; Slattery J; Houÿez F; Haerry D; Genov G; Arlett P
Drug Saf; 2017 Jul; 40(7):629-645. PubMed ID: 28417320
[TBL] [Abstract][Full Text] [Related]
11. Paediatric adverse drug reactions following use of asthma medications in Europe from 2007 to 2011.
Aagaard L; Hansen EH
Int J Clin Pharm; 2014 Dec; 36(6):1222-9. PubMed ID: 25288145
[TBL] [Abstract][Full Text] [Related]
12. Adverse drug reactions in children reported by European consumers from 2007 to 2011.
Aagaard L; Hansen EH
Int J Clin Pharm; 2014 Apr; 36(2):295-302. PubMed ID: 24190692
[TBL] [Abstract][Full Text] [Related]
13. Signal detection of human papillomavirus vaccines using the Korea Adverse Events Reporting System database, between 2005 and 2016.
Ran J; Yang JY; Lee JH; Kim HJ; Choi JY; Shin JY
Int J Clin Pharm; 2019 Oct; 41(5):1365-1372. PubMed ID: 31313003
[TBL] [Abstract][Full Text] [Related]
14. A Pharmacovigilance Signaling System Based on FDA Regulatory Action and Post-Marketing Adverse Event Reports.
Hoffman KB; Dimbil M; Tatonetti NP; Kyle RF
Drug Saf; 2016 Jun; 39(6):561-75. PubMed ID: 26946292
[TBL] [Abstract][Full Text] [Related]
15. An analysis of the trends, characteristics, scope, and performance of the Zimbabwean pharmacovigilance reporting scheme.
Masuka JT; Khoza S
Pharmacol Res Perspect; 2020 Oct; 8(5):e00657. PubMed ID: 32930524
[TBL] [Abstract][Full Text] [Related]
16. Geographical variation in reporting Interstitial Lung Disease as an adverse drug reaction: findings from an European Medicines Agency analysis of reports in EudraVigilance.
Pinheiro L; Blake K; Januskiene J; Yue QY; Arlett P
Pharmacoepidemiol Drug Saf; 2016 Jun; 25(6):705-12. PubMed ID: 27004571
[TBL] [Abstract][Full Text] [Related]
17. Comparison between paediatric and adult suspected adverse drug reactions reported to the European medicines agency: implications for pharmacovigilance.
Blake KV; Zaccaria C; Domergue F; La Mache E; Saint-Raymond A; Hidalgo-Simon A
Paediatr Drugs; 2014 Aug; 16(4):309-19. PubMed ID: 24898717
[TBL] [Abstract][Full Text] [Related]
18. Signal Detection for Cardiovascular Adverse Events of DPP-4 Inhibitors Using the Korea Adverse Event Reporting System Database, 2008-2016.
Yi H; Lee JH; Shin JY
Yonsei Med J; 2019 Feb; 60(2):200-207. PubMed ID: 30666842
[TBL] [Abstract][Full Text] [Related]
19. Triptans and serious adverse vascular events: data mining of the FDA Adverse Event Reporting System database.
Roberto G; Piccinni C; D'Alessandro R; Poluzzi E
Cephalalgia; 2014 Jan; 34(1):5-13. PubMed ID: 23921799
[TBL] [Abstract][Full Text] [Related]
20. Influence of age, sex and seriousness on reporting of adverse drug reactions in Sweden.
Holm L; Ekman E; Jorsäter Blomgren K
Pharmacoepidemiol Drug Saf; 2017 Mar; 26(3):335-343. PubMed ID: 28071845
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
